Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

The Zephyr Valve procedure is a minimally invasive treatment for severe or very severe COPD and emphysema. It offers an alternative to highly invasive options like lung transplants, which carry ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

You may have COPD if you notice persistent, prolonged changes to your breathing. Symptoms can include: These symptoms usually worsen over time without treatment. You can also develop conditions ...